Formula Growth’s SOPHiA GENETICS SOPH Stock Holding History

Formula Growth’s Portfolio SOPH Stock Details SOPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.13M	Buy	+254,000	New	+$1.83M	0.82%	37

Other funds holding SOPH

Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return

AKRE Capital Management Middleburg, Virginia $4.42B AUM 17.77% 1-Year Est. Return

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

AIC

AWM Investment Company New York $1.04B AUM 103.31% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return

Alta Wealth Advisors Woburn, Massachusetts $380M AUM 32.41% 1-Year Est. Return

Next Century Growth Investors Plymouth, Minnesota $1.57B AUM 96.5% 1-Year Est. Return

Walleye Capital New York $109B AUM 29.28% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

Formula Growth's SOPH Position: Q3 2026 in Review

Formula Growth opened a new position in SOPHiA GENETICS (SOPH) in Q3 2026: 254,000 shares worth $2.13M. The stake represents 0.82% of the portfolio and ranks #37 among its holdings.

69 funds tracked by Wall St. Rank hold SOPH as of Q3 2026.

Formula Growth held 254,000 shares of SOPHiA GENETICS worth $2.13M as of Q3 2026.
SOPHiA GENETICS was a new Formula Growth position in Q3 2026.
SOPHiA GENETICS made up 0.82% of Formula Growth's portfolio in Q3 2026, its #37 holding.
69 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q3 2026.

Based on Formula Growth's 13F filing for Q3 2026, filed 13 Nov 2026.